ATE525390T1 - Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes - Google Patents

Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes

Info

Publication number
ATE525390T1
ATE525390T1 AT00930170T AT00930170T ATE525390T1 AT E525390 T1 ATE525390 T1 AT E525390T1 AT 00930170 T AT00930170 T AT 00930170T AT 00930170 T AT00930170 T AT 00930170T AT E525390 T1 ATE525390 T1 AT E525390T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
resistin
specific antibodies
resistant specific
Prior art date
Application number
AT00930170T
Other languages
English (en)
Inventor
Mitchell Lazar
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE525390T1 publication Critical patent/ATE525390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
AT00930170T 1999-04-27 2000-04-27 Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes ATE525390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13126399P 1999-04-27 1999-04-27
PCT/US2000/011272 WO2000064920A1 (en) 1999-04-27 2000-04-27 Compositions, methods, and kits relating to resistin

Publications (1)

Publication Number Publication Date
ATE525390T1 true ATE525390T1 (de) 2011-10-15

Family

ID=22448669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930170T ATE525390T1 (de) 1999-04-27 2000-04-27 Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes

Country Status (5)

Country Link
US (3) US20020161210A1 (de)
EP (1) EP1180114B1 (de)
AT (1) ATE525390T1 (de)
AU (1) AU4803800A (de)
WO (1) WO2000064920A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525390T1 (de) * 1999-04-27 2011-10-15 Univ Pennsylvania Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
CA2445499A1 (en) * 2001-03-30 2002-10-10 Genentech, Inc. Fizz1 for metabolism regulation
CA2444028A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
AU2003224720A1 (en) * 2002-04-08 2003-10-27 Eli Lilly And Company Use of resistin to treat hematopoietic disorders
IL149851A0 (en) * 2002-05-26 2002-11-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
US20040023383A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of resistin expression
IL151980A0 (en) * 2002-09-29 2003-04-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
US20040248183A1 (en) * 2003-06-09 2004-12-09 George Argyropoulos Method of identifying and treating insulin-resistant individuals who are responsive to anti-oxidant therapy
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
US20060099608A1 (en) * 2004-03-29 2006-05-11 Medstar Research Institute Methods of diagnosing cardiovascular disease
US7795390B2 (en) * 2005-06-24 2010-09-14 Teijin Pharma Limited Biological substance nesfatin and its related substances and uses thereof
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
US8343491B2 (en) * 2006-12-18 2013-01-01 The Johns Hopkins University Anti-HIMF antibodies to treat lung diseases
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
WO2012048414A1 (en) * 2010-10-12 2012-04-19 Mcmaster University A method of regulating plasma lipoproteins
EP3010934A4 (de) 2013-06-17 2017-01-11 The Johns Hopkins University Antikörper gegen humanes resistin
EP3261582B1 (de) 2015-02-26 2021-01-06 Remodeless CV Ltd. Verfahren und zusammensetzungen in zusammenhang mit leptin-antagonisten

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
EP0696322A1 (de) * 1993-04-26 1996-02-14 University Of Victoria Innovation And Development Corporation Verfahren und zusammensetzungen fuer salmonella basierte impfstoffe
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO1999011293A1 (en) * 1997-09-05 1999-03-11 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999055868A2 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
AU7962398A (en) * 1997-06-19 1999-01-04 Schering Corporation Mammalian genes; related reagents
US20020111476A1 (en) * 1997-06-19 2002-08-15 Karin Franz-Bacon Mammalian genes; related reagents
US20030166906A1 (en) * 1997-09-05 2003-09-04 Human Genome Sciences, Inc. 50 human secreted proteins
WO2000005259A1 (en) * 1998-07-23 2000-02-03 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
AU766279B2 (en) * 1998-10-06 2003-10-16 Curagen Corporation Novel secreted proteins and polynucleotides encoding them
ATE525390T1 (de) * 1999-04-27 2011-10-15 Univ Pennsylvania Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
AU2001268232A1 (en) * 2000-06-09 2001-12-24 The Trustees Of The University Of Pennsylvania Compositions, methods, and kits relating to resistin-like molecules
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease

Also Published As

Publication number Publication date
US20140030267A1 (en) 2014-01-30
WO2000064920A9 (en) 2002-06-27
US20070104708A1 (en) 2007-05-10
WO2000064920A1 (en) 2000-11-02
US20020161210A1 (en) 2002-10-31
EP1180114A4 (de) 2004-08-04
EP1180114A1 (de) 2002-02-20
EP1180114B1 (de) 2011-09-21
AU4803800A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE176498T1 (de) Xylanase, entsprechende rekombinante dna-sequenz, xylanase enthaltendes agens, und seine verwendung
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE126970T1 (de) Proteinhydrolysate.
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
FI922204A0 (fi) Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma.
ATE195346T1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
DK244289D0 (da) Fibronectinbindende protein, dets anvendelse og fremstilling samt midler til brug ved fremstillingen
IT1252174B (it) Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE69110952D1 (de) Penicillin-G-Acylase, dafür kodierendes Gen und Verfahren zur Herstellung von diesem Enzym.
DK0885296T3 (da) Et enzym med galactanaseaktivitet
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
ATE192494T1 (de) Verwendung einer herpesprotease
ATE106250T1 (de) Verwendung von antikörper-antigen-wechselwirkung zum schutz oder modulation der biologischen aktivität.
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
ATE348171T1 (de) Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
DE69132159D1 (de) Merosin, dafür kodierende nukleinsäuren, fragmente und deren verwendung
DE69433902D1 (de) Neuartige tyrosinkinase
DE3686786D1 (de) Menschliche proteine des chinolinesterase-typs und ihre herstellung.
ATE109796T1 (de) Gewebeinhibitor für metalloproteasen (timp-2).
DE60112476D1 (de) Glucuronyl-c5-epimerase der maus, diese codierende dna und deren verwendung
DE3850456D1 (de) Klonierung des isoamylaseenzym kodierenden Gens und seine Verwendung zur Herstellung dieses Enzyms.
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties